Contemporary management and rechallenge practices for 5-fluorouracil-associated cardiotoxicity: an international cardio-oncology society survey

Clicks: 1
ID: 323361
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #197 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background 5-fluorouracil (5-FU)–associated coronary vasospasm is a clinically important cardiotoxicity often leading to cancer therapy interruption, yet evidence guiding acute management and safe rechallenge is limited. We surveyed International Cardio-Oncology Society (ICOS) members to define contemporary practice patterns, variability in care, and barriers to rechallenge. Methods An electronic survey was distributed to ICOS members. Of 152 responses, 133 were analyzed after exclusions; item-level denominators had variable completion. Practices were summarized, compared by practice type and years of cardio-oncology experience, using chi-square/Fisher’s exact tests (two-sided p<0.05). Results Most respondents practiced at academic centers (59.1%, 78/132) and had <5 (36.4%, 48/132), 5–10 (38.6%, 51/132), or >10 years (25.0%, 33/132) of cardio-oncology experience. In response to 5-FU treatment, chest pain (91.0%, 121/133), ST-segment changes (54.9%, 73/133), and troponin elevation (40.6%, 54/133) were commonly observed. Symptom onset was <24 h (25.2%, 33/131), 1–3 d (44.3%, 58/131), >3 d (5.3%, 7/131), or variable (25.2%,33/131). Mortality attributable to 5-FU cardiotoxicity was reported by 23.3% (31/133). Initial work up included electrocardiography (93.2%, 123/132), troponin measurement (87.1%, 115/132), and echocardiography (79.5%, 105/132). Urgent coronary angiography was pursued in 35.6% (47/132) of cases and routinely in 84.1% (111/132). Acute management strategies varied, including 5-FU discontinuation (76.5%, 101/132), nitrates (69.7%, 92/132) or calcium channel blockers (59.8%, 79/132), and telemetry (50.0%, 66/132) or ICU-level care (26.5%, 35/132). ICOS respondents were involved in rechallenge decisions in 70.0% (91/130) and 93.8% (122/130) co-managed with oncology. Strategies included vasodilator pre-treatment (74.2%, 92/124), dose reduction (45.2%, 56/124), bolus-only dosing (33.1%, 41/124), and switch to capecitabine (29.8%, 37/124). 91.2% (103/113) reported success in ≥50% of rechallenge cases. Institutional protocols were reported as present (18.3%, 23/126) or in development (22.2%, 28/126); 24.4% (30/123) reported lack of clear guidelines as a practice barrier to rechallenge. Academic ICOS respondents more often reported always/frequently communicating directly with oncology (97.4% vs 86.8%; p=0.03). More years in cardio-oncology practice was associated with rechallenge involvement (p<0.01, and guideline gaps were reported as an impediment to rechallenge (p<0.01). Conclusion In a survey of ICOS members, management and rechallenge practices for suspected 5-FU–cardiotoxicity varied substantially. Rechallenge was commonly attempted with vasodilator prophylaxis and monitored re-exposure, yet formal protocols are uncommon, and guideline gaps persist. Our study underscores the need for consensus recommendations and prospective studies to inform risk stratification and safer 5-FU rechallenge strategies.
Reference Key
openalex_W7172271360 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors S Byer, B Loeffler, A K Yadalam, A Stein-Merlob, A K Ghosh, D Addison, C Chandrasekharan, E H Yang, M G Fradley, U S Grewal
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.171
URL
https://doi.org/10.1093/eurheartjsupp/suag097.171
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.